Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: nuwellis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $17.00 | Buy | ROTH MKM |
D - Nuwellis, Inc. (0001506492) (Filer)
S-1 - Nuwellis, Inc. (0001506492) (Filer)
10-Q - Nuwellis, Inc. (0001506492) (Filer)
8-K - Nuwellis, Inc. (0001506492) (Filer)
8-K - Nuwellis, Inc. (0001506492) (Filer)
8-K - Nuwellis, Inc. (0001506492) (Filer)
EFFECT - Nuwellis, Inc. (0001506492) (Filer)
424B3 - Nuwellis, Inc. (0001506492) (Filer)
D - Nuwellis, Inc. (0001506492) (Filer)
S-1/A - Nuwellis, Inc. (0001506492) (Filer)
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights: Received a 297% CMS reimbursement increase to $1,639 for Aquadex facility fee, effective January 1, 2025.Revenue of $2.4 million.Pediatrics revenue growth of 28% compared to the prior year quarter.Gross margin of 70%, compared to 57.3% in the prior-year quarter.Total operating cost reduction of 30% compared to the prior-year quarter.New study published in Current Problems in Cardiology highlighted statistically significan
MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million o
Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reimbursement level most consistent with administration of ultrafiltration therapy and cost of treatment. Effective January 1, 2025, the payment rate will increase 397% from $413 to $1,639 per day. Ne
MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. Based on preliminary, unaudited results, management expects the Company to report the following in respect of its quarterly period ended September 30, 2024: Revenue of approximately $2.4 million.Revenue growth of 28% in the Pediatric customer category compared to the same period
MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family Children's Hospital in Iowa City, Iowa, has adopted the Aquadex SmartFlow® system to treat pediatric patients suffering from fluid overload due to heart and kidney disease. The Stead Family Children's Hospital will use the Aquadex SmartFlow system to provide adjustable ultrafiltration therapy for critically ill children experiencing excess fluid buildup. This therapy will allow for safe and effective fluid removal, which is critical in managing
MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-445-7795 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ3. An aud
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners' third annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024. Investor presentations and other materials used at the conference will be available on the investor relations section of Nuwellis' website. Parties interested in attending the conference and meeting with Nuwellis may contact their ROTH representative, submit a registration request online, or contact Vivian Ce
MINNEAPOLIS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce the publication of a new study in Current Problems in Cardiology demonstrating the effectiveness of Aquadex® ultrafiltration therapy in reducing 60 day hospital readmission rates for patients with acutely decompensated heart failure (ADHF) who are otherwise resistant to diuretic treatment. The study, conducted by Viswanath R. Chinta, MD, Dr. John L. Jefferies, MD, MBA, MPH, and fellow researchers, is titled "Outcomes of Ultrafiltration in community-based hospitals" and sought to evaluate and va
MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 496,901 shares of the Company's common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 496,901 shares of common stock. The warrants have an exercise pri
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2024. Highlights: Revenue of $2.2 million, a 6% increase over the second quarter of 2023.Critical Care revenue growth of 28% compared to the prior year quarter; Heart Failure consumables utilization growth of 35% over the prior-year quarter. Gross margin of 67.2%, compared to 55.3% in the prior-year quarter.Total operating cost reduction of 38% compared to the prior-year quarter.Expanded Aquadex® to pediatric patients at one of the largest hospital n
ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G/A - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G/A - Nuwellis, Inc. (0001506492) (Subject)
SC 13G/A - Nuwellis, Inc. (0001506492) (Subject)
SC 13G/A - Nuwellis, Inc. (0001506492) (Subject)
4 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
3 - Nuwellis, Inc. (0001506492) (Issuer)
3 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
3 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
3 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights: Received a 297% CMS reimbursement increase to $1,639 for Aquadex facility fee, effective January 1, 2025.Revenue of $2.4 million.Pediatrics revenue growth of 28% compared to the prior year quarter.Gross margin of 70%, compared to 57.3% in the prior-year quarter.Total operating cost reduction of 30% compared to the prior-year quarter.New study published in Current Problems in Cardiology highlighted statistically significan
MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. Based on preliminary, unaudited results, management expects the Company to report the following in respect of its quarterly period ended September 30, 2024: Revenue of approximately $2.4 million.Revenue growth of 28% in the Pediatric customer category compared to the same period
MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-445-7795 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ3. An aud
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter of 2024 on Tuesday, August 13, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-267-6316 (U.S) or 1-203-518-9783 (international) and using the conference ID: NUWEQ2. An aud
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10188299. An audi
MINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022.Fourth quarter pediatric revenue grew 35% year over year; 28% increase in utilization and a 49% increase in console sales. Four new pediatric accounts.Fourth quarter gross margin of 54.4%. Full year 2023 gross margin of 56.2%, a 56-basis point increase over full year 2022
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10
MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and u
MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2023. Revenue of $2.1 million for the second quarter 2023, representing a 14% increase over the prior quarter and a 6% decrease over the prior-year period.Utilization, or the number of circuits per console, increased 14% over the same period last year, reflecting an increase in the number of patients treated with the Aquadex therapy.By segment, second quarter 2023 revenue in Heart Failure increased approximately 8% over the same period last year,
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and usin
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience
MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board
MINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO). In this new role, Dr. Jefferies will provide Nuwellis with strategic guidance on clinical and medical affairs issues, act as a liaison between the Company and the medical community and serve as a key advisor on corporate development matters. "I am thrilled to welcome Dr. Jefferies in this new role of CMO," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "Dr. Jefferies' pediatric training and expertise in car
EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 100 points on Wednesday. The Dow traded down 0.82% to 40,025.48 while the NASDAQ fell 2.92% to 17,472.06. The S&P 500 also fell, dropping, 1.84% to 5,453.67. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.8% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 3%. Top Headline Shares of AT&T Inc. (NYSE:T) rose around 5% during Wednesday’s session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 500 points on Wednesday. The Dow traded down 0.76% to 40,052.02 while the NASDAQ fell 2.89% to 17,476.46. The S&P 500 also fell, dropping, 1.75% to 5,458.52. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.8% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 3%. Top Headline Tesla Inc (NASDAQ:TSLA) shares dipped more than 11% on Wednesday on the heels of the company's second-quarter financial results. The EV maker noted that it expects 2024 vehicle volume
U.S. stocks traded lower this morning, with the Dow Jones dipping around 400 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.99% to 39,957.30 while the NASDAQ fell 2.08% to 17,622.81. The S&P 500 also fell, dropping, 1.47% to 5,473.80. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.3% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 2.7%. Top Headline Alphabet Inc (NASDAQ:GOOG) posted better-than-expected earnings and sales results for its second quarter. Alphabet reported second-quarter revenue of $84.742
Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of $4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of $3.99 per share, will be exercisable immediate
Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to announce its first commercial sale of QUELIMMUNE™, a novel therapy developed by SeaStar Medical Holding Corporation for pediatric patients suffering from an uncontrolled inflammatory response triggered by their immune systems, to Cincinnati Children's. We believe this milestone marks a significant advancement in pediatric critical care and underscores Nuwellis' commitment to revolutionizing pediatric patient outcomes. QUELIMMUNE, or Selective Cytopheretic Device for pediatrics, represents a transformative solution for pediatric patients sufferi
Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Mainz Biomed shares jumped 16% to $0.5534 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pineapple Energy Inc. (NASDAQ:PEGY) rose 85% to $2.22 in pre-market trading. Pineapple Energy engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 43.5% to $13.26 in pre-market trading after gaining 127% on Mon